Publicaciones en colaboración con investigadores/as de Institute Paoli-Calmettes (17)

2022

  1. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 710.e1-710.e10

  2. Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation

2021

  1. Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 3, pp. 655-663

2020

  1. Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

    Blood, Vol. 135, Núm. 13, pp. 996-1007

  2. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma – a LWP-EBMT study

    British Journal of Haematology, Vol. 188, Núm. 5, pp. 745-756

2018

  1. Rituximab plus lenalidomide in advanced untreated follicular lymphoma

    New England Journal of Medicine, Vol. 379, Núm. 10, pp. 934-946

2017

  1. Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

    International Journal of Molecular Sciences, Vol. 18, Núm. 4

  2. Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    Haematologica, Vol. 102, Núm. 10, pp. 1767-1775

  3. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481

  4. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. International collaborative study on EUS-guided gallbladder drainage: Are we ready for prime time?

    Digestive and Liver Disease, Vol. 48, Núm. 9, pp. 1054-1057

2015

  1. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

    British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354

  2. KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis

    Leukemia, Vol. 29, Núm. 6, pp. 1223-1232

2013

  1. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma

    Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255

2011

  1. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial

    The Lancet, Vol. 377, Núm. 9759, pp. 42-51

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886